Patients and Families Asked to Share their Experiences about AZLI

November 18, 2008

The CF Foundation has written to the Food and Drug Administration (FDA) requesting that the agency reconsider a drug application for a new therapy called Aztreonam Lysine for Inhalation (AZLI). 

AZLI is a promising new inhaled antibiotic treatment that appears to help combat the pulmonary symptoms of cystic fibrosis.
The Foundation is now asking people with CF, their families and others with personal experience with AZLI to share their stories. By sharing a brief message about how AZLI has made an impact on your health, you can help the Foundation as it works with the FDA to move this new therapy forward.

Please download this letter and write a few words about what AZLI has done for you. Then, email it to We’ll make sure that the FDA hears your message.

Read additional information about AZLI and the importance of the drug for CF care.